***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Background Pooled data from two large registries , Cubicin ® Outcomes Registry and Experience ( CORE ; USA ) and European Cubicin ® Outcomes Registry and Experience ( EU-CORE ; Europe , Latin America , and Asia ) , were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions . Methods Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included .  Clinical success was defined as an outcome of ‘ cured ’ or ‘ improved ’ . Post-treatment follow-up data were collected for a subset of patients ( CORE : osteomyelitis and orthopedic foreign body device infection ; EU-CORE : endocarditis , intracardiac/intravascular device infection , osteomyelitis , and orthopedic device infection ) .  Safety was assessed for up to 30 days after daptomycin treatment . Results In 11,557 patients ( CORE , 5482 ; EU-CORE , 6075 ) treated with daptomycin ( median age , 62 [ range , 1–103 ] years ) , the most frequent underlying conditions were cardiovascular disease ( 54.7 % ) and diabetes mellitus ( 28.0 % ) . The most commonly treated primary infections were complicated skin and soft tissue infection ( cSSTI ; 31.2 % ) and bacteremia ( 21.8 % ) . The overall clinical success rate was 77.2 % ( uncomplicated SSTI , 88.3 % ; cSSTI , 81.0 % ; osteomyelitis , 77.7 % ; foreign body/prosthetic infection ( FBPI ) , 75.9 % ; endocarditis , 75.4 % ; and bacteremia , 69.5 % ) . The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections ( MRSA , 78.1 % ) . An increasing trend of high-dose daptomycin ( > 6 mg/kg/day ) prescribing pattern was observed over time . Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI . Adverse events ( AEs ) and serious AEs possibly related to daptomycin therapy were reported in 628 ( 5.4 % ) and 133 ( 1.2 % ) patients , respectively . Conclusions The real-world data showed that daptomycin  was effective and safe in the treatment of various Gram-positive infections , including those caused by resistant pathogens , across wide geographical regions Daptomycin is the first available agent from a new class of antibiotics , the cyclic lipopeptides , that has activity against a broad range of gram-positive pathogens , including organisms that are resistant to methicillin , vancomycin , and other currently available agents . Daptomycin ( 4 mg/kg intravenously [ iv ] every 24 h for 7 - 14 days ) was compared with conventional antibiotics ( penicillinase-resistant penicillins [ 4 - 12 g iv per day ] or vancomycin [ 1 g iv every 12 h ] ) in 2 r and omized , international trials involving 1092 patients with complicated skin and skin-structure infections . Among 902 clinical ly evaluable patients , clinical success rates were 83.4 % and 84.2 % for the daptomycin- and comparator-treated groups , respectively ( 95 % confidence interval , -4.0 to 5.6 ) . Among patients successfully treated with iv daptomycin , 63 % required only 4 - 7 days of therapy , compared with 33 % of comparator-treated patients ( P<.0001 ) . The frequency and distribution of adverse events were similar among both treatment groups . Overall , the safety and efficacy of daptomycin were comparable with conventional therapy Daptomycin is a lipopeptide antibiotic active against gram-positive organisms and recently approved for marketing in Japan . This study investigates the efficacy and safety of daptomycin in Japanese patients with skin and soft tissue infections ( SSTIs ) caused by methicillin-resistant Staphylococcus aureus ( MRSA ) for regulatory filing in Japan . Overall , 111 Japanese patients with SSTI were r and omized in this open-label , r and omized , active-comparator controlled , parallel-group , multicenter , phase III study . Patients received intravenous daptomycin 4 mg/kg once daily or vancomycin 1 g twice daily for 7–14 days . Efficacy was determined by a blinded Efficacy Adjudication Committee . Among patients with SSTIs caused by MRSA , 81.8 % ( 95 % CI , 69.1–90.9 ) of daptomycin recipients and 84.2 % ( 95 % CI , 60.4–96.6 ) of vancomycin recipients achieved a successful clinical response at the test-of-cure ( TOC ) visit . The microbiological success rate against MRSA at the TOC visit was 56.4 % ( 95 % CI , 42.3–69.7 ) with daptomycin and 47.4 % ( 95 % CI , 24.4–71.1 ) with vancomycin . Daptomycin was generally well tolerated ; most adverse events were of mild to moderate severity . The measurement of daptomycin concentration in plasma revealed that patients with mild or moderate impaired renal function showed similar pharmacokinetics profiles to patients with normal renal function . Clinical and microbiological responses , stratified by baseline MRSA susceptibility , suggested that patients infected with MRSA of higher daptomycin MIC showed a trend of lower clinical success with a P value of 0.052 by Cochran – Armitage test . Daptomycin was clinical ly and microbiologically effective for the treatment of MRSA-associated SSTIs in Japanese patients Background : Results from previous trials suggest that daptomycin may result in faster clinical improvement than penicillinase-resistant penicillins or vancomycin for patients with complicated skin and skin structure infections . Objective : The objective was to evaluate whether daptomycin treatment of cellulitis or erysipelas would result in faster resolution compared with vancomycin . Design : The study was a prospect i ve , evaluator-blinded , multi-centre trial . Patients were r and omised to receive daptomycin 4 mg/kg once daily or vancomycin according to st and ard of care for 7–14 days . Patients : Adults diagnosed with cellulitis or erysipelas requiring hospitalisation and intravenous antibiotic therapy were eligible for enrolment . Results : The clinical success rates were 94.0 % for daptomycin and 90.2 % for vancomycin ( 95 % confidence interval for the difference , −6.7 % , 14.3 % ) . There were no statistically significant differences between treatment arms in the time to resolution or improvement in any of the predefined clinical end-points . Both daptomycin and vancomycin were well tolerated . Conclusions : There was no difference in the rate of resolution of cellulitis or erysipelas among patients treated with daptomycin or vancomycin . Daptomycin 4 mg/kg once daily appeared to be effective and safe for treating cellulitis or erysipelas BACKGROUND Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed . METHODS We r and omly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of body weight daily and 122 to receive initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin . The primary efficacy end point was treatment success 42 days after the end of therapy . RESULTS Forty-two days after the end of therapy in the modified intention-to-treat analysis , a successful outcome was documented for 53 of 120 patients who received daptomycin as compared with 48 of 115 patients who received st and ard therapy ( 44.2 percent vs. 41.7 percent ; absolute difference , 2.4 percent ; 95 percent confidence interval , -10.2 to 15.1 percent ) . Our results met prespecified criteria for the noninferiority of daptomycin . The success rates were similar in subgroups of patients with complicated bacteremia , right-sided endocarditis , and methicillin-resistant S. aureus . Daptomycin therapy was associated with a higher rate of microbiologic failure than was st and ard therapy ( 19 vs. 11 patients , P=0.17 ) . In 6 of the 19 patients with microbiologic failure in the daptomycin group , isolates with reduced susceptibility to daptomycin emerged ; similarly , a reduced susceptibility to vancomycin was noted in isolates from patients treated with vancomycin . As compared with daptomycin therapy , st and ard therapy was associated with a nonsignificantly higher rate of adverse events that led to treatment failure due to the discontinuation of therapy ( 17 vs. 8 , P=0.06 ) . Clinical ly significant renal dysfunction occurred in 11.0 percent of patients who received daptomycin and in 26.3 percent of patients who received st and ard therapy ( P=0.004 ) . CONCLUSIONS Daptomycin ( 6 mg per kilogram daily ) is not inferior to st and ard therapy for S. aureus bacteremia and right-sided endocarditis . ( Clinical Trials.gov number , NCT00093067 [ Clinical Trials.gov ] . ) Background Daptomycin has proven efficacy in patients with Gram-positive complicated skin and soft tissue infections ( cSSTIs ) , including those caused by Staphylococcus aureus , regardless of methicillin susceptibility . Objective This study was undertaken to evaluate the efficacy and safety of daptomycin in elderly patients . Study Design This was an open-label , multicentre , r and omized phase IIIb study conducted in hospitalized patients Patients Patients aged ≥65 years with a diagnosis of Gram-positive cSSTIs with or without bacteraemia were included . In addition , infections were required to be of sufficient severity to require inpatient hospitalization and treatment with parenteral antibiotics for at least 96 h. The main exclusion criterion was the presence of a non-complicated SSTI that could heal by itself or be cured by surgical removal of the site of infection . Intervention Patients were r and omized ( 2:1 ) to intravenous daptomycin or pooled intravenous st and ard therapies ( semi-synthetic penicillin or vancomycin , referred to as the ‘ comparator ’ ) . Duration of treatment was between 5 and 14 days for cSSTIs without bacteraemia and between 10 and 28 days for cSSTIs with bacteraemia . Main Outcome MeasureThe primary objective was descriptive comparison of clinical success in clinical ly evaluable patients at test of cure , 7–14 days post treatment . Secondary objectives were microbiological outcome , duration of treatment and safety . Results In total , 120 patients were r and omized ( 81 to daptomycin ; 39 to the comparator ) and 102 patients completed the study . Baseline characteristics were similar between the two groups . Common infections included cellulitis , ulcers and abscesses ; six patients had bacteraemia [ five documented ( daptomycin , n = 3 ; comparator , n = 2 ) ; and one suspected ( daptomycin , n = 1 ) ] . Test-of-cure clinical success rates were numerically higher for daptomycin than for the comparator [ 89.0 % ( 65/73 ) vs. 83.3 % ( 25/30 ) ; odds ratio 1.65 ( 95 % confidence interval 0.49–5.54 ) ] . For patients with S. aureus infections , cure rates were 89.7 % ( 35/39 ) versus 69.2 % ( 9/13 ) , respectively ; percentage points difference , 20.5 ( 95 % confidence interval −12.2 to 50.9 ) ] . Rates of adverse events ( AEs ) and serious AEs were similar in both treatment arms ; however , discontinuation rates for AEs/serious AEs were lower for daptomycin than for the comparator ( 3.8 % vs. 10.0 % ) . Three serious AEs were considered to be related to the study drug : one case each of pancytopenia  ( semi-synthetic penicillin )  , renal failure  ( vancomycin ) and asymptomatic increase in creatine phosphokinase concentrations  ( daptomycin ) . Conclusion In elderly patients , for whom data were previously limited , the efficacy and safety of daptomycin have been confirmed , including for infections caused by S. aureus , regardless of methicillin susceptibility Background : Staphylococcus aureus , including community-associated methicillin-resistant S. aureus , is an important cause of pediatric bacteremia .  Daptomycin is a well-established treatment option for Gram-positive bacteremia in adults , but its safety and efficacy in children require confirmation . Methods : This was a r and omized ( 2:1 ) , 
    Output:
    
Conclusions : No significant differences in treatment failure rates and safety were found using daptomycin or any of the comparators treatment